Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Jaguar Health's board has initiated a process to explore strategic alternatives, including potential mergers or acquisitions, to maximize stockholder value in alignment with its anticipated NDA filing for crofelemer. Third-party market research estimates the market for the rare intestinal failure indication at $1.1 billion in 2026, growing to $1.5 billion by 2033.
Key figures
- Drug Name
- crofelemer
- Mvid market 2026
- $1.1 billion
- Mvid market 2033
- $1.5 billion
- Parenteral support reduction
- up to 37%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.